{
  "docId": "019de072-ece7-71de-8eba-0df52639d987",
  "docSlug": "f4caf3b83872d8591c78c133c07757ed",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 19 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 19,
  "prevPage": 18,
  "nextPage": null,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The chart compares actual/projected pipeline growth against an 'Industry Standard' benchmark line.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ece7-71de-8eba-0df52639d987/19",
  "deckHref": "/decks/019de072-ece7-71de-8eba-0df52639d987",
  "deckJsonHref": "/decks/019de072-ece7-71de-8eba-0df52639d987.json",
  "deckAnchorHref": "/decks/019de072-ece7-71de-8eba-0df52639d987#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.7,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Delivered 12 named programmes by end 2021 including 1 Phase I/II (Atopic Dermatitis) and 1 Preclinical (Ulcerative Colitis). Building a deep in-house clinical pipeline with commercial launches targeted by end of the decade. Supplemented by out-licensed assets.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33cdf348-08d0-4c3a-848c-7b1afc5cd846",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "2020 - 2025 In-House Pipeline Progression",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99fc708c-165b-436b-b4c6-57c94329c763",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Company filings and estimates. Paul et al (2010) and BIO (2021) for industry standards",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a942cab5-9fa2-4b3b-bb3b-d3c0db39134f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BenevolentAI is positioned to productionize drug development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3d431fe-3ef1-4c1b-a2e6-23432f31725e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}